LEADER 03074nam 2200601 450 001 9910131531803321 005 20230808212415.0 010 $a1-118-91434-1 010 $a1-118-81958-6 010 $a1-118-81944-6 035 $a(CKB)3710000000498432 035 $a(EBL)4435614 035 $a(MiAaPQ)EBC4435614 035 $a(DLC) 2015030480 035 $a(Au-PeEL)EBL4435614 035 $a(CaPaEBR)ebr11169625 035 $a(CaONFJC)MIL902575 035 $a(OCoLC)915775232 035 $a(EXLCZ)993710000000498432 100 $a20160331h20162016 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aAttrition in the pharmaceutical industry $ereasons, implications, and pathways forward /$fedited by Alexander Alex, C. John Harris, Dennis A. Smith 210 1$aHoboken, New Jersey :$cWiley,$d2016. 210 4$d©2016 215 $a1 online resource (373 p.) 300 $aIncludes index. 311 $a1-118-67967-9 320 $aIncludes bibliographical references and index. 327 $aAttrition in drug discovery and development / Scott Boyer, Clive Brealey and Andrew M. Davis -- Compound attrition at the pre-clinical phase / Cornelis E.C.A. Hop -- Attrition in phase I / Dennis A. Smith and Thomas A. Baillie -- Compound attrition in phase II/III / Alexander Alex, C. John Harris, Wilma W. Keighley and Dennis A. Smith -- Post-marketing attrition / Dennis A. Smith -- Influence of the regulatory environment on attrition / Robert T. Clay -- Experimental screening strategies to reduce attrition risk / Marie-Claire Peakman, Matthew Troutman, Rose Gonzales and Anne Schmidt -- Medicinal chemistry strategies to prevent compound attrition / J. Richard Morphy -- Influence of phenotypic and target-based screening strategies on compound attrition and project choice / Andrew Bell, Wolfgang Fecke and Christine Williams -- In silico approaches to address compound attrition / Peter Gedeck, Christian Kramer, Richard Lewis -- Current and future strategies for improving drug discovery efficiency / Peter Mbugua Njogu and Kelly Chibale -- Impact of investment strategies, organizational structure and corporate environment on attrition, and future investment strategies to reduce attrition / Geoff Lawton. 606 $aPharmaceutical industry$xManagement 606 $aPharmaceutical industry$xCapital productivity 606 $aIndustrial efficiency 606 $aDrug development 615 0$aPharmaceutical industry$xManagement. 615 0$aPharmaceutical industry$xCapital productivity. 615 0$aIndustrial efficiency. 615 0$aDrug development. 676 $a615.1068/5 700 $aAlex$b Alexander A.$01242845 702 $aAlex$b Alexander 702 $aHarris$b C. John 702 $aSmith$b Dennis A. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910131531803321 996 $aAttrition in the pharmaceutical industry$92882999 997 $aUNINA LEADER 01227nam0 22003373i 450 001 MIL0069587 005 20251003044221.0 010 $a0521352789 100 $a20090127d1991 ||||0itac50 ba 101 | $aeng 102 $agb 181 1$6z01$ai $bxxxe 182 1$6z01$an 200 1 $aˆThe ‰detection of gravitational waves$fedited by David G. Blair 210 $aCambridge$cCambridge university press$d1991 215 $aXXIV, 481 p.$cill.$d26 cm. 606 $aOnde gravitazionali$xMisurazione$2FIR$3NAPC279831$9I 676 $a531$9Meccanica classica. Meccanica dei solidi$v14 676 $a531.14$9MECCANICA. MASSA E GRAVITA$v22 696 $aMisura$aMisurazioni 699 $aMisurazione$zMisura 699 $aMisurazione$zMisurazioni 702 1$aBlair$b, David G.$3MILV048165 801 3$aIT$bIT-000000$c20090127 850 $aIT-BN0095 901 $bNAP 01$cSALA DING $n$ 912 $aMIL0069587 950 0$aBiblioteca Centralizzata di Ateneo$b1 v.$c1 v.$d 01SALA DING 531 DETOGW$e 0102 0000028175 VMA A4 1 v. (rist. 1993)$fY $h19970909$i19970909 977 $a 01 996 $aDetection of gravitational waves$91572020 997 $aUNISANNIO